#scalability

Manufacturing targeted biologics requires flexibility and an ability to handle small numbers of high-value batches at an increased frequency. It requires greater process flexibility, versatile equipment, and a more agile approach.

Scalability is what the market is in search of.

As biopharma pipelines grow, there is increasing demand to produce multiple therapies in parallel. All of this means that sterile injectable manufacturing capabilities have to meet the need for improved scalability. This enables flexible, multi-product, small batch production, minimizing product waste and cross-contamination between drugs.

INJECTA’s robotic multi-format filling system design meets multiple requirements, ranging from small-scale clinical trial batches up to medium-high production levels. Its unique production platform, which implements any number of filling pumps between one and ten, performs the same identical filling, check-weighing and stoppering operations avoiding re-qualification of the production process.

INJECTA, performing the same operations without process re-qualification, enhances your production efficiency.

The filling system implemented on INJECTA relies upon a unique driving system for volumetric and peristaltic pumps and a filling nozzle approved for integration in single-use package forms. Similarly, its 100% check-weighing system can count upon the same HW components for the weighing cells, the same change over parts  and the same SW process.

When handling syringes, stoppering operations are performed with the same deep tube and vacuum insertion. In the case of vial stoppering, all operational sequences are identical for both lyo & non-lyo stoppers. When it comes to handling the new integrated rubber & plastic caps, recently introduced on the market, INJECTA handles them in the same way.

The INJECTA family in all configurations ensures unique, standardised sterilisation, filling and stoppering performance, leading to improved product quality and superior manufacturing efficiency.